JP2021105043A - 非溶媒和物結晶及びその製造方法、並びに応用 - Google Patents
非溶媒和物結晶及びその製造方法、並びに応用 Download PDFInfo
- Publication number
- JP2021105043A JP2021105043A JP2021065323A JP2021065323A JP2021105043A JP 2021105043 A JP2021105043 A JP 2021105043A JP 2021065323 A JP2021065323 A JP 2021065323A JP 2021065323 A JP2021065323 A JP 2021065323A JP 2021105043 A JP2021105043 A JP 2021105043A
- Authority
- JP
- Japan
- Prior art keywords
- solvate crystal
- solvate
- crystal
- methoxyquinoline
- aminophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 133
- 239000012453 solvate Substances 0.000 title claims abstract description 112
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- BRKWREZNORONDU-UHFFFAOYSA-N n-(2-aminophenyl)-6-(7-methoxyquinolin-4-yl)oxynaphthalene-1-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=C1C=CC=2)=CC=C1C=2C(=O)NC1=CC=CC=C1N BRKWREZNORONDU-UHFFFAOYSA-N 0.000 claims abstract description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 15
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 10
- 108060006633 protein kinase Proteins 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000005856 abnormality Effects 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 31
- 238000000862 absorption spectrum Methods 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 102000003964 Histone deacetylase Human genes 0.000 claims description 8
- 108090000353 Histone deacetylase Proteins 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000006197 histone deacetylation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 18
- 229920002472 Starch Polymers 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 18
- 239000008108 microcrystalline cellulose Substances 0.000 description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 229910052708 sodium Inorganic materials 0.000 description 18
- 239000008107 starch Substances 0.000 description 18
- 235000019698 starch Nutrition 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 239000008101 lactose Substances 0.000 description 10
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 7
- -1 7-methoxyquinoline-4-oxy Chemical group 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UQDVHJGNIFVBLG-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O UQDVHJGNIFVBLG-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Science and Practice of Pharmacy(第19版,1995年)に記載の方法により得られることができ、それは、援用により本明細書に組み込まれる。前記組成物は、例えば、錠剤、カプセル、散剤、顆粒剤、懸濁剤、シロップ剤、液剤、注射剤、膏剤などの一般的医薬調製物の形態として見られる。その製剤は、通常、式(I)で表される化合物0.5%〜70%wt、及び医薬品添加物30%〜99.5%wtを含み、好ましくは、1%〜65%wt、3%〜60%wt、5%〜55%wt、10%〜50%wt、20%〜40%wt、25%〜38%wt、30%〜35%wt又は32%〜34%wtの式(I)で表される化合物を含む。
実施例2:N−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶Bの調製
実施例3:N−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶Cの調製
実施例4:結晶形の安定性試験
実施例5:実施例1の非溶媒和物結晶Aの錠剤の調製
処方(1000錠):
実施例1の非溶媒和物結晶A 5g
微結晶セルロース 90g
カルボキシメチルスターチナトリウム 5g
4% ポリビニルピロリドン(K30)エタノール溶液 50g
タルク粉末 0.5g
実施例6:実施例1の非溶媒和物結晶Aのカプセルの調製
処方(1000錠):
実施例1の非溶媒和物結晶A 5g
微結晶セルロース 55g
ラクトース 35g
カルボキシメチルスターチナトリウム 5g
ステアリン酸マグネシウム 0.5g
実施例7:実施例2の非溶媒和物結晶Bの錠剤の調製
処方(1000錠):
実施例2の非溶媒和物結晶B 5g
微結晶セルロース 90g
カルボキシメチルスターチナトリウム 5g
4% ポリビニルピロリドン(K30)エタノール溶液 50g
タルク粉末 0.5g
実施例8:実施例2の非溶媒和物結晶Bのカプセルの調製
処方(1000錠):
実施例2の非溶媒和物結晶B 5g
微結晶セルロース 55g
ラクトース 35g
カルボキシメチルスターチナトリウム 5g
ステアリン酸マグネシウム 0.5g
実施例9:実施例3の非溶媒和物結晶Cの錠剤の調製
処方(1000錠):
実施例3の非溶媒和物結晶C 5g
微結晶セルロース 90g
カルボキシメチルスターチナトリウム 5g
4% ポリビニルピロリドン(K30)エタノール溶液 50g
タルク粉末 0.5g
実施例10:実施例3の非溶媒和物結晶Cのカプセルの調製
処方(1000錠):
実施例3の非溶媒和物結晶C 5g
微結晶セルロース 55g
ラクトース 35g
カルボキシメチルスターチナトリウム 5g
ステアリン酸マグネシウム 0.5g
Claims (15)
- N−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶であって、
前記非溶媒和物結晶は、非溶媒和物結晶A、非溶媒和物結晶B、及び非溶媒和物結晶Cから選択され、
前記非溶媒和物結晶Aは、粉末X線回折パターンにおいて回折角(2θ)6.88°、9.26°、12.74°、13.82°、18.58°、20.86°及び25.72°に特徴的なピークを有し、
前記非溶媒和物結晶Bは、粉末X線回折パターンにおいて回折角(2θ)4.88°、9.68°、12.74°、14.52°、17.72°、24.30°、25.26°に特徴的なピークを有し、
前記非溶媒和物結晶Cは、粉末X線回折パターンにおいて回折角(2θ)4.84°、9.68°、12.92°、14.60°、16.46°、17.44°、22.00°、25.28°に特徴的なピークを有する、非溶媒和物結晶。 - 前記非溶媒和物結晶は、前記非溶媒和物結晶Aであり、
前記非溶媒和物結晶Aは、粉末X線回折パターンにおいて回折角(2θ)4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、18.58°、20.86°及び25.72°に特徴的なピークを有する、請求項1に記載の非溶媒和物結晶。 - 前記非溶媒和物結晶Aは、粉末X線回折パターンにおいて回折角(2θ)4.42°、6.88°、8.78°、9.26°、12.74°、13.82°、15.78°、18.58°、20.86°、22.56°、25.72°、27.08°及び28.72°に特徴的なピークを有する、請求項2に記載の非溶媒和物結晶。
- 前記非溶媒和物結晶Aの赤外吸収スペクトルは、3452、3404、3357、3230、3064、1622、1576、1525、1506、1452、1423、1388、1363、1311、1253、1224、1161、1088及び1024cm-1に特徴的な吸収ピークを有し、及び/又は、その示差走査熱量曲線において177.5℃、213.1℃及び220.8℃に吸熱ピークを有する、請求項1〜3のいずれか一項に記載の非溶媒和物結晶。
- 前記非溶媒和物結晶は、前記非溶媒和物結晶Bであり、
前記非溶媒和物結晶Bは、粉末X線回折パターンにおいて回折角(2θ)4.88°、9.68°、12.74°、14.52°、17.72°、19.82°、21.86°、24.30°、25.26°に特徴的なピークを有する、請求項1に記載の非溶媒和物結晶。 - 前記非溶媒和物結晶Bの赤外吸収スペクトルは、3423、3352、3238、3030、1624、1597、1531、1502、1452、1423、1388、1365、1308、1255、1226、1159、1086、1022cm-1に特徴的な吸収ピークを有し、及び/又は、その示差走査熱量曲線において178.6℃に吸熱ピークを有する、請求項5に記載の非溶媒和物結晶。
- 前記非溶媒和物結晶は、前記非溶媒和物結晶Cであり、
前記非溶媒和物結晶Cは、粉末X線回折パターンにおいて回折角(2θ)4.84°、9.68°、12.92°、14.60°、16.46°、17.44°、17.88°、22.00°、25.28°、27.66°に特徴的なピークを有する、請求項1に記載の非溶媒和物結晶。 - 前記非溶媒和物結晶Cは、粉末X線回折パターンにおいて回折角(2θ)4.84°、9.68°、12.92°、14.60°、16.46°、17.20°、17.44°、17.88°、19.20°、20.54°、21.06°、22.00°、25.28°、27.66°に特徴的なピークを有する、請求項7に記載の非溶媒和物結晶。
- 前記非溶媒和物結晶Cの赤外吸収スペクトルは、3452、3369、3217、3016、2962、1793、1728、1626、1595、1574、1531、1502、1448、1429、1388、1311、1252、1224、1159、1020cm-1に特徴的な吸収ピークを有し、及び/又は、その示差走査熱量曲線において196.3℃及び221.0℃に吸熱ピークを有する、請求項1、7、及び8のいずれか一項に記載の非溶媒和物結晶。
- N−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドをメタノールに加え、65℃で加熱して溶解させ、0℃まで冷却して析出させるステップを含む、請求項1〜4のいずれか1項に記載のN−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶Aの製造方法。
- N−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドをアセトニトリルに加え、80℃で加熱して溶解させ、0℃まで冷却して析出させるステップを含む、請求項1、5、及び6のいずれか1項に記載のN−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶Bの製造方法。
- N−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドをジメチルスルホキシドに加え、室温で撹拌して溶解させた溶液を撹拌しながら水に滴下し、固体をろ過し収集するステップを含む、請求項1、及び7〜9のいずれか1項に記載のN−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶Cの製造方法。
- 請求項1〜9のいずれか1項に記載のN−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶を含む医薬組成物。
- 請求項1〜9のいずれか1項に記載のN−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶を含む、プロテインキナーゼ活性異常、又はヒストン脱アセチル化酵素活性異常に関連する疾患を治療するための医薬組成物。
- 請求項1〜9のいずれか1項に記載のN−(2−アミノフェニル)−6−(7−メトキシキノリン−4−イルオキシ)−1−ナフトアミドの非溶媒和物結晶の、プロテインキナーゼ活性異常、又はヒストン脱アセチル化酵素活性異常に関連する疾患を治療するための使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610856945.2 | 2016-09-27 | ||
CN201610856945.2A CN107868044B (zh) | 2016-09-27 | 2016-09-27 | 一种非溶剂化晶体及其制备方法与应用 |
JP2019517848A JP7339884B2 (ja) | 2016-09-27 | 2017-09-27 | 非溶媒和物結晶及びその製造方法、並びに応用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019517848A Division JP7339884B2 (ja) | 2016-09-27 | 2017-09-27 | 非溶媒和物結晶及びその製造方法、並びに応用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021105043A true JP2021105043A (ja) | 2021-07-26 |
Family
ID=61751435
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019517848A Active JP7339884B2 (ja) | 2016-09-27 | 2017-09-27 | 非溶媒和物結晶及びその製造方法、並びに応用 |
JP2021065323A Withdrawn JP2021105043A (ja) | 2016-09-27 | 2021-04-07 | 非溶媒和物結晶及びその製造方法、並びに応用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019517848A Active JP7339884B2 (ja) | 2016-09-27 | 2017-09-27 | 非溶媒和物結晶及びその製造方法、並びに応用 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10882825B2 (ja) |
EP (1) | EP3524594A4 (ja) |
JP (2) | JP7339884B2 (ja) |
KR (1) | KR20190053952A (ja) |
CN (1) | CN107868044B (ja) |
AU (1) | AU2017333056B2 (ja) |
BR (1) | BR112019005995A2 (ja) |
CA (1) | CA3038384C (ja) |
MX (1) | MX2019003458A (ja) |
RU (1) | RU2019112457A (ja) |
TW (1) | TWI724242B (ja) |
UA (1) | UA123746C2 (ja) |
WO (1) | WO2018059429A1 (ja) |
ZA (1) | ZA201902628B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107868044B (zh) * | 2016-09-27 | 2020-10-16 | 深圳微芯生物科技股份有限公司 | 一种非溶剂化晶体及其制备方法与应用 |
CN109908143B (zh) * | 2018-12-18 | 2021-11-19 | 厦门大学附属第一医院 | 西奥罗尼在制备治疗急性髓系白血病药物的新用途 |
US11578041B2 (en) * | 2020-04-21 | 2023-02-14 | Genovate Biotechnology Co. Ltd. | Crystals of hydroxychloroquine sulfate |
KR20230066401A (ko) * | 2020-09-09 | 2023-05-15 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | 항종양 치료법에서 면역 체크포인트 억제제와 조합된 치아우라닙의 용도 |
CN117597124A (zh) * | 2021-07-08 | 2024-02-23 | 深圳微芯生物科技股份有限公司 | 西奥罗尼及其联合用药治疗乳腺癌的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100298358A1 (en) * | 2009-05-22 | 2010-11-25 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors |
JP2012528800A (ja) * | 2009-06-04 | 2012-11-15 | シンセン チップスクリーン バイオサイエンセズ リミテッド | プロテインキナーゼおよびヒストンデアセチラーゼの阻害剤としてのナフタレンカルボキサミド誘導体、その製造方法および用途 |
JP2019529504A (ja) * | 2016-09-27 | 2019-10-17 | シンセン チップスクリーン バイオサイエンセズ カンパニー リミテッド | 非溶媒和物結晶及びその製造方法、並びに応用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103833626B (zh) * | 2012-11-27 | 2015-11-25 | 深圳微芯生物科技有限责任公司 | 西达本胺的晶型及其制备方法与应用 |
CN103288728A (zh) * | 2013-05-17 | 2013-09-11 | 华侨大学 | 一种萘甲酰胺衍生物、其制备方法以及应用 |
CN103896836A (zh) * | 2014-03-20 | 2014-07-02 | 华侨大学 | N-苯基-6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺及其制备方法 |
CN103923004A (zh) * | 2014-04-04 | 2014-07-16 | 华侨大学 | 一种萘甲酰胺衍生物及其制备和应用 |
-
2016
- 2016-09-27 CN CN201610856945.2A patent/CN107868044B/zh active Active
-
2017
- 2017-09-27 BR BR112019005995A patent/BR112019005995A2/pt active Search and Examination
- 2017-09-27 EP EP17854879.8A patent/EP3524594A4/en active Pending
- 2017-09-27 RU RU2019112457A patent/RU2019112457A/ru unknown
- 2017-09-27 KR KR1020197012102A patent/KR20190053952A/ko not_active IP Right Cessation
- 2017-09-27 CA CA3038384A patent/CA3038384C/en active Active
- 2017-09-27 UA UAA201904447A patent/UA123746C2/uk unknown
- 2017-09-27 TW TW106133220A patent/TWI724242B/zh active
- 2017-09-27 AU AU2017333056A patent/AU2017333056B2/en active Active
- 2017-09-27 US US16/337,389 patent/US10882825B2/en active Active
- 2017-09-27 WO PCT/CN2017/103620 patent/WO2018059429A1/zh unknown
- 2017-09-27 JP JP2019517848A patent/JP7339884B2/ja active Active
- 2017-09-27 MX MX2019003458A patent/MX2019003458A/es unknown
-
2019
- 2019-04-25 ZA ZA2019/02628A patent/ZA201902628B/en unknown
-
2021
- 2021-04-07 JP JP2021065323A patent/JP2021105043A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100298358A1 (en) * | 2009-05-22 | 2010-11-25 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors |
JP2012528800A (ja) * | 2009-06-04 | 2012-11-15 | シンセン チップスクリーン バイオサイエンセズ リミテッド | プロテインキナーゼおよびヒストンデアセチラーゼの阻害剤としてのナフタレンカルボキサミド誘導体、その製造方法および用途 |
JP2019529504A (ja) * | 2016-09-27 | 2019-10-17 | シンセン チップスクリーン バイオサイエンセズ カンパニー リミテッド | 非溶媒和物結晶及びその製造方法、並びに応用 |
Non-Patent Citations (5)
Title |
---|
厚生労働省医薬局審査管理課長: "新医薬品の規格及び試験方法の設定について", 医薬審発第568号, JPN6015027393, 1 May 2001 (2001-05-01), ISSN: 0004774396 * |
厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, vol. 第307号, JPN6014031669, 1998, pages 1 - 11, ISSN: 0004947972 * |
川口洋子ら, 生活工学研究, vol. 4, no. 2, JPN6015027394, 2002, pages 310 - 317, ISSN: 0004774395 * |
平山令明, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004947970 * |
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0004947971 * |
Also Published As
Publication number | Publication date |
---|---|
US10882825B2 (en) | 2021-01-05 |
US20200031774A1 (en) | 2020-01-30 |
AU2017333056B2 (en) | 2020-07-02 |
EP3524594A1 (en) | 2019-08-14 |
CA3038384C (en) | 2021-11-02 |
CN107868044B (zh) | 2020-10-16 |
UA123746C2 (uk) | 2021-05-26 |
JP7339884B2 (ja) | 2023-09-06 |
WO2018059429A1 (zh) | 2018-04-05 |
JP2019529504A (ja) | 2019-10-17 |
RU2019112457A3 (ja) | 2020-11-02 |
BR112019005995A2 (pt) | 2019-07-09 |
RU2019112457A (ru) | 2020-11-02 |
ZA201902628B (en) | 2021-09-29 |
TWI724242B (zh) | 2021-04-11 |
CN107868044A (zh) | 2018-04-03 |
CA3038384A1 (en) | 2018-04-05 |
KR20190053952A (ko) | 2019-05-20 |
AU2017333056A1 (en) | 2019-05-02 |
TW201813957A (zh) | 2018-04-16 |
MX2019003458A (es) | 2019-10-15 |
EP3524594A4 (en) | 2020-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021105043A (ja) | 非溶媒和物結晶及びその製造方法、並びに応用 | |
JP2020183408A (ja) | {[5−(3−クロロフェニル)−3−ヒドロキシピリジン−2−カルボニル]アミノ}酢酸の固体形態、組成物、及びその使用 | |
JP6457658B2 (ja) | 安定した、溶媒和物が含まれないアプレミラスト結晶形ii、及びその製造方法 | |
JP2018530610A (ja) | ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法 | |
WO2014082354A1 (zh) | 西达本胺的晶型及其制备方法与应用 | |
KR102522895B1 (ko) | Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법 | |
JP2020504124A (ja) | (r)−4−ヒドロキシ−2−オキソ−1−ピロリジンアセトアミドの結晶形、その調製方法および使用 | |
JP7303821B2 (ja) | ピリミジニルアミノ-ピラゾール化合物の多形体及び固体形態、ならびに製造方法 | |
TWI672302B (zh) | Bcl-2抑制劑之新結晶型、其製備方法及含其之醫藥組合物 | |
TWI708764B (zh) | 一種雄性激素受體抑制劑的結晶形式及其製備方法 | |
CN105646520A (zh) | 一种稳定的艾日布林化合物 | |
JP2016533361A (ja) | ピラゾロピリジン化合物の固体形態 | |
CA2961819C (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
EP2886543A1 (en) | Crystalline form of mastinib mesylate | |
JP2022508864A (ja) | チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法 | |
CN108137626A (zh) | Fosnetupitant的晶型 | |
CN106458975B (zh) | 达比加群酯甲磺酸盐的晶型及其制备方法和用途 | |
CN109824569B (zh) | 一种西罗多辛晶型i及其制备方法 | |
CA2999009C (en) | Crystal form of 4-((1-methylpyrrol-2-yl)-carbonyl)-n-(4-(4-morpholin-1-yl-carbonylpiperidin-1-yl)-phenyl)-1-piperazinecarboxamide monohydrate | |
CN105646583A (zh) | 一种稳定的头孢洛林化合物 | |
RU2669777C2 (ru) | Кристаллические формы темозоломида и способ получения таковых | |
KR20220113418A (ko) | 아세틸콜린에스테라제 억제제의 결정형 및 이의 제조 방법과 응용 | |
KR20190005679A (ko) | 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법 | |
CN106061983A (zh) | 吡嗪并[2,1‑c][1,2,4]三嗪化合物的晶体(1) | |
TW201518276A (zh) | 吲哚衍生物之鹽及其結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220517 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221220 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20230303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230704 |